附近上门

Two months after announcing its Series B investment, San Mateo-based is back with a $75 million Series C round of funding to launch an at-home lab testing network by the end of the year.

Subscribe to the 附近上门 Daily

We last caught up with Truepill in July when the 4-year-old startup was expanding its pharmacy fulfillment business. The company works with health plans, pharmaceutical manufacturers and consumer health brands by providing a business-to-business model for building direct-to-patient experiences from the ground up that includes a telehealth network, pharmacy fulfillment and a custom-built EMR.

The new at-home lab testing service adds the 鈥渢hird leg of the stool鈥� to Truepill鈥檚 platform, , Truepill鈥檚 co-founder and president, told 附近上门 News.

鈥淐OVID-19 has been an accelerator for everything in health care,鈥� he said. 鈥淚t was very clear that when we thought about the platform, there was a third piece missing of diagnostics to provide a true platform. Now, later this year, we will have all three. To think about the Series C, it is a testament to being the right company in the right circumstances.鈥�

led the round with participation from existing investors , , and . Including the new funding, Truepill has raised $114 million since it was founded in 2016, according to 附近上门 data. That includes the $25 million Series B and a investment led by in 2019.

The new funding will be used to launch the testing network with hundreds of different tests available for women鈥檚 and men鈥檚 health, fertility, general panels, STIs and eventually COVID, Viswanathan said. In addition, Truepill is focusing on patients with chronic disease.

鈥淵ou will be able to go from a telehealth visit with your doctor to the lab for tests and then get a drug for any treatment,鈥� he added. 鈥淚t is the end-to-end vision that we are making a reality.鈥�

Illustration: